trending Market Intelligence /marketintelligence/en/news-insights/trending/dlnivy3bvkdytjqvvvk7pg2 content esgSubNav
In This List

US court dismisses suit against Biogen related to blockbuster drug Tecfidera

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


US court dismisses suit against Biogen related to blockbuster drug Tecfidera

Biogen Inc. is no longer facing a lawsuit that alleged it misled shareholders on the financial performance and safety of its blockbuster drug Tecfidera, Reuters reported.

U.S. District Judge Dennis Saylor tossed the lawsuit out on grounds that plaintiffs failed to establish the company's executives made false or misleading statements intentionally or recklessly.

The Cambridge, Mass.-based biotechnology company's Tecfidera — a treatment for multiple sclerosis — generated $4.2 billion in sales in 2017.